Research progress on prescription and medication patterns and pharmacological mechanisms of traditional Chinese medicine for colorectal cancer cachexia based on theory of reinforcing healthy qi and dispelling pathogen
XIE Zhenming, WANG Jinghui, HUANG Wenqi, WU Jiao, LI Gao, WANG Dingxue, HE Fan, WU Wenyu, TANG Dongxin
Affiliations
1 Guizhou University of Traditional Chinese Medicine, Guiyang 550025, China; 2 The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang 550001, China; 3 Tumor Inheritance and Technological Innovation Talent Base of TCM in Guizhou Province, Guiyang 550002, China; 4 The Affiliated Hospital of Zunyi Medical University, Zunyi 563000, China
Colorectal cancer (CRC) cachexia is a common wasting syndrome in patients with advanced CRC. It is mainly characterized by progressive skeletal muscle wasting, lipolysis, systemic inflammatory response, and metabolic and immune dysregulation, which seriously impair patients’quality of life, treatment tolerance, and prognosis. In traditional Chinese medicine (TCM), this disease is generally classified into the category of “consumptive disease”, with its core pathogenesis characterized by “deficiency in origin and excess in superficiality” and “deficiency and excess inclusiofuzhengquxie”. Reinforcing healthy qi and dispelling pathogen are regarded as the principal therapeutic principles. By retrieving relevant domestic and international literature, this review systematically summarizes the pathogenesis of CRC cachexia, the regularity of syndrome differentiation and treatment in TCM, and the characteristics of the Application of prescriptions and drugs. Furthermore, it elucidates the pharmacological mechanisms by which active ingredients and Chinese herbal formulas intervene in cachexia through regulating inflammatory networks, improving skeletal muscle and adipose tissue metabolism, protecting mitochondrial function, and reshaping the immune microenvironment. Specifically, “reinforcing healthy qi” corresponds to the improvement of nutritional metabolism, protection of skeletal muscle, and regulation of immune function, whereas “dispelling pathogen” corresponds to the inhibition of inflammation, remodeling of the tumor microenvironment, and blockade of abnormal catabolism, thereby constructing a correlation between TCM therapeutic principles and the inflammation-metabolism-immunity regulatory network.
Key words
colorectal cancer cachexia
/
reinforcing healthy qi and dispelling pathogen
/
prescription and medication patterns
/
inflammation-metabolism-immunity regulation
/
mitochondrial function
XIE Zhenming, WANG Jinghui, HUANG Wenqi, WU Jiao, LI Gao, WANG Dingxue, HE Fan, WU Wenyu, TANG Dongxin.
Research progress on prescription and medication patterns and pharmacological mechanisms of traditional Chinese medicine for colorectal cancer cachexia based on theory of reinforcing healthy qi and dispelling pathogen[J].
Chinese Traditional and Herbal Drugs,
2026
, 57
(17)
: 6973
-6984
.
DOI: 10.7501/j.issn.0253-2670.2026.17.027
Siegel R L, Kratzer T B, Giaquinto A N, et al. Cancer statistics, 2025[J]. CA A Cancer J Clin, 2025, 75(1): 10-45. Huot J R, Novinger L J, Pin F, et al. HCT116 colorectal liver metastases exacerbate muscle wasting in a mouse model for the study of colorectal cancer cachexia [J]. Dis Model Mech, 2020, 13(1): dmm043166. Dajani O, Philips I, Størkson E K, et al. Oncological and survival endpoints in cancer cachexia clinical trials: Systematic review 6 of the cachexia endpoints series [J]. J Cachexia Sarcopenia Muscle, 2025, 16(2): e13756. Kasprzak A. The role of tumor microenvironment cells in colorectal cancer (CRC) cachexia [J]. Int J Mol Sci, 2021, 22(4): 1565. Crunkhorn S. A new target for cancer cachexia [J]. Nat Rev Drug Discov, 2025, 24(5): 333. 谢贞明, 吴文宇, 黄雯琪, 等. 基于扶正祛邪理论探讨结直肠癌恶病质的免疫-炎症调控机制及干预策略[J]. 中医杂志, 2026, 67(12): 1267-1271. 贺倩文, 刘冬静, 刘燕, 等. 六君子汤干预IL-6/STAT3信号影响肿瘤环境下C2C12细胞分化机制的研究[J]. 世界科学技术—中医药现代化, 2021, 23(10): 3630-3637. 孟祥瑀. 加味半夏厚朴汤联合甲地孕酮治疗肺鳞癌恶液质的临床观察及机制探究[D]. 天津: 天津中医药大学, 2022. 霍晨星, 田建辉, 姚源, 等.“形神共治”在肿瘤终末期恶液质中的策略与意义[J]. 世界科学技术—中医药现代化, 2026, 28(5): 1429-1437. 陈晟, 段熔辉, 刘正艺, 等. 基于数据挖掘、网络药理学和动物实验探究中药治疗癌症恶病质用药规律及作用机制[J]. 中草药, 2026, 57(6): 2216-2233. Fearon K, Strasser F, Anker S D, et al. Definition and classification of cancer cachexia: An international consensus [J]. Lancet Oncol, 2011, 12(5): 489-495. Seelaender M, Batista M Jr, Lira F, et al. Inflammation in cancer cachexia: To resolve or not to resolve (is that the question?) [J]. Clin Nutr, 2012, 31(4): 562-566. Mao H M, Zhao X C, Sun S C. NF-κB in inflammation and cancer [J]. Cell Mol Immunol, 2025, 22(8): 811-839. Zhang Y Q, Nipp R D, Janowitz T, et al. Cancer cachexia: A tumor-driven disorder of whole-body homeostasis [J]. Cancer Cell, 2026, 44(5): 913-932. Zhu X A, Starosta S, Ferrer M, et al. A neuroimmune circuit mediates cancer cachexia-associated apathy [J]. Science, 2025, 388(6743): eadm8857. Bonetto A, Aydogdu T, Jin X L, et al. JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia [J]. Am J Physiol Endocrinol Metab, 2012, 303(3): E410-E421. Chen L, Chen L L, Wan L L, et al. Matrine improves skeletal muscle atrophy by inhibiting E3 ubiquitin ligases and activating the Akt/mTOR/FoxO3α signaling pathway in C2C12 myotubes and mice [J]. Oncol Rep, 2019, 42(2): 479-494. Bowers M, Petrasso C, McLuskie A, et al. Multicomponent interventions for adults with cancer cachexia: A systematic review [J]. J Cachexia Sarcopenia Muscle, 2025, 16(2): e13716. Santos Silva K A, Dong J L, Dong Y J, et al. Inhibition of STAT3 activation suppresses Caspase-3 and the ubiquitin-proteasome system, leading to preservation of muscle mass in cancer cachexia [J]. J Biol Chem, 2015, 290(17): 11177-11187. Schweitzer K, Pralow A, Naumann M. p97/VCP promotes Cullin-RING-ubiquitin-ligase/proteasome-dependent degradation of IκBα and the preceding liberation of RelA from ubiquitinated IκBα [J]. J Cell Mol Med, 2016, 20(1): 58-70. Xu Y T, Xu X Y, Zhang Q Y, et al. Gp130-dependent STAT3 activation in M-CSF-derived macrophages exaggerates tumor progression [J]. Genes Dis, 2024, 11(3): 100985. Siddiqui J A, Pothuraju R, Jain M, et al. Advances in cancer cachexia: Intersection between affected organs, mediators, and pharmacological interventions [J]. Biochim Biophys Acta Rev Cancer, 2020, 1873(2): 188359. Zhu X X, Callahan M F, Gruber K A, et al. Melanocortin-4 receptor antagonist TCMCB07 ameliorates cancer- and chronic kidney disease-associated cachexia [J]. J Clin Invest, 2020, 130(9): 4921-4934. Fang R X, Yan L, Liao Z K. Abnormal lipid metabolism in cancer-associated cachexia and potential therapy strategy [J]. Front Oncol, 2023, 13: 1123567. Kliewer K L, Ke J Y, Tian M, et al. Adipose tissue lipolysis and energy metabolism in early cancer cachexia in mice [J]. Cancer Biol Ther, 2015, 16(6): 886-897. Murphy R A, Wilke M S, Perrine M, et al. Loss of adipose tissue and plasma phospholipids: Relationship to survival in advanced cancer patients [J]. Clin Nutr, 2010, 29(4): 482-487. van der Ende M, Grefte S, Plas R, et al. Mitochondrial dynamics in cancer-induced cachexia [J]. Biochim Biophys Acta BBA Rev Cancer, 2018, 1870(2): 137-150. Padrão A I, Oliveira P, Vitorino R, et al. Bladder cancer-induced skeletal muscle wasting: Disclosing the role of mitochondria plasticity [J]. Int J Biochem Cell Biol, 2013, 45(7): 1399-1409. Liu M Y, Ren Y, Zhou Z J, et al. The crosstalk between macrophages and cancer cells potentiates pancreatic cancer cachexia [J]. Cancer Cell, 2024, 42(5): 885-903.e4. Tilg H, Ianiro G, Gasbarrini A, et al. Adipokines: Masterminds of metabolic inflammation [J]. Nat Rev Immunol, 2025, 25(4): 250-265. Cui Q H, Li S J, Liu X D, et al. MIF-ACKR3 causes irreversible fat loss by impairing adipogenesis in cancer cachexia [J]. Cell Metab, 2025, 37(4): 954-970. Muscaritoli M, Arends J, Bachmann P, et al. ESPEN practical guideline: Clinical nutrition in cancer [J]. Clin Nutr, 2021, 40(5): 2898-2913. Arends J, Strasser F, Gonella S, et al. Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines [J]. ESMO Open, 2021, 6(3): 100092. Roeland E J, Bohlke K, Baracos V E, et al. Management of cancer cachexia: ASCO guideline [J]. J Clin Oncol, 2020, 38(21): 2438-2453. 吴煜, 杨宇飞, 杨焕明. 中药反应性基因: 中药抗肿瘤恶病质研究的新切入点[J]. 世界科学技术, 2000, 2(1): 17-18. 中国抗癌协会肿瘤营养专业委员会, 中华医学会肠外肠内营养学分会, 李涛. 放疗患者的营养治疗指南(2024版) [J]. 肿瘤代谢与营养电子杂志, 2024, 11(5): 629-637. 王杰敏, 贾维慧, 厉丹阳, 等. 肺癌患者恶病质的药物治疗与营养支持研究进展[J]. 中国肺癌杂志, 2022, 25(6): 420-424. Tan Y T, Xue R, Pan Y W, et al. Cancer cachexia: Molecular basis and therapeutic advances [J]. Signal Transduct Target Ther, 2026, 11(1): 16. 缪克团. 绝经后女性骨质疏松症与肌少症及性激素相关性研究[D]. 合肥: 安徽中医药大学, 2020. Millrine D, Kishimoto T. A brighter side to thalidomide: Its potential use in immunological disorders [J]. Trends Mol Med, 2017, 23(4): 348-361. Tatematsu N. Exercise therapy for cancer cachexia [J]. Gan To Kagaku Ryoho, 2022, 49(7): 732-736. Grande A J, Silva V, Sawaris Neto L, et al. Exercise for cancer cachexia in adults [J]. Cochrane Database Syst Rev, 2021, 2021(3): CD010804. Argilés J M, López-Soriano F J, Stemmler B, et al. Cancer-associated cachexia: Understanding the tumour macroenvironment and microenvironment to improve management [J]. Nat Rev Clin Oncol, 2023, 20(4): 250-264. 柯刚, 董清科, 肖世容, 等. 基于网络药理学探讨参苓白术散治疗肿瘤恶病质的作用机制[J]. 药学实践与服务, 2025, 43(5): 242-250. 张旭, 杨国旺, 佟丽. 基于骨骼肌代谢探讨从“脾肾”“气血”论治癌性恶液质[J]. 中医药学报, 2024, 52(12): 6-10. 彭梦薇, 刘燕, 张艳, 等. 蛋白合成与降解信号参与肿瘤恶病质肌肉萎缩及中医药调节机制研究进展[J]. 中国比较医学杂志, 2023, 33(7): 123-129. 李科, 谭诗生. 中药调节肠道菌群改善肿瘤恶液质作用的研究进展[J]. 现代肿瘤医学, 2022, 30(9): 1690-1694. 温丽娜, 贾平平, 石汉平. 知母-黄柏药对“异病同治”肿瘤恶液质及糖尿病的整合机制研究[J]. 中药新药与临床药理, 2022, 33(6): 804-812. 王晞星, 刘丽坤, 何院生, 等. 大肠癌恶病质中医证型研究[J]. 世界中西医结合杂志, 2010, 5(11): 953-955. 何院生, 王晞星, 刘丽坤, 等. 因子分析方法探讨大肠癌恶病质辨证要点[J]. 中国民间疗法, 2020, 28(13): 77-78. 刘丽坤, 王晞星, 李宜放, 等. 大肠癌恶病质中医证型与影响因素的相关性研究[J]. 辽宁中医杂志, 2013, 40(7): 1358-1360. 凡晓菲. 结直肠癌恶液质中医证型相关因素分析及生存期临床观察[D]. 太原: 山西省中医药研究所, 2024. 张顺玉, 陈沁秋, 许晓燕, 等. 中药治疗肿瘤恶液质的用药规律挖掘及分析[J]. 中国医药导报, 2025, 22(31): 49-54. 丁琦, 刘华, 孙铜林. 基于数据挖掘技术探究癌症食欲不振-恶病质综合征的遣方用药规律[J]. 亚太传统医药, 2022, 18(4): 163-168. 赵朝庭, 王静, 何舟. 中医治疗癌性厌食恶病质综合征的临床研究进展[J]. 广西医科大学学报, 2018, 35(8): 1162-1165. Webster J M, Kempen L J A P, Hardy R S, et al. Inflammation and skeletal muscle wasting during cachexia [J]. Front Physiol, 2020, 11: 597675. Ruan G T, Xie H L, Yuan K T, et al. Prognostic value of systemic inflammation and for patients with colorectal cancer cachexia [J]. J Cachexia Sarcopenia Muscle, 2023, 14(6): 2813-2823. Tsoli M, Robertson G. Cancer cachexia: Malignant inflammation, tumorkines, and metabolic mayhem [J]. Trends Endocrinol Metab, 2013, 24(4): 174-183. 佘春燕, 张学梅, 马海英. 黄连素改善小鼠结肠腺癌恶病质实验研究[J]. 实用肿瘤杂志, 2014, 29(6): 547-551. Shen Q, Kuang J X, Miao C X, et al. Alantolactone ameliorates cancer cachexia-associated muscle atrophy mainly by inhibiting the STAT3 signaling pathway [J]. Phytomedicine, 2022, 95: 153858. 徐玲, 张学进, 杨国良. 四君子汤对癌性恶病质小鼠血清细胞因子的影响[J]. 中华中医药学刊, 2015, 33(4): 907-910. 潘磊, 翁家武, 陈培丰. 参附注射液对C26结肠癌荷瘤小鼠恶病质状态改善作用的实验研究[J]. 中国中医药科技, 2012, 19(6): 502-503. 张敏, 李贵新, 马长庚, 等. 参芪扶正注射液联合吲哚美辛对小鼠癌性恶病质发生及细胞因子干预的影响[J]. 临床合理用药杂志, 2011, 4(9): 21-23. 张欣慰, 梁天宇. 益气健脾抗癌方改善肠癌化疗患者恶液质状态疗效分析[J]. 辽宁中医药大学学报, 2024, 26(12): 194-198. 刘超. 保元解毒汤改善癌性恶病质生存质量及骨骼肌萎缩的机制研究[D]. 济南: 山东中医药大学, 2014. 高文侠, 葛小栋, 王建桥, 等. 自拟健脾益气汤联合甲地孕酮对结肠癌食欲不振-恶病质综合征的临床疗效观察[J]. 中国中西医结合消化杂志, 2023, 31(3): 192-196. Chen L L, Xu W H, Yang Q J, et al. Imperatorin alleviates cancer cachexia and prevents muscle wasting via directly inhibiting STAT3[J]. Pharmacol Res, 2020, 158: 104871. Chen L L, Yang Q J, Zhang H, et al. Cryptotanshinone prevents muscle wasting in CT26-induced cancer cachexia through inhibiting STAT3 signaling pathway [J]. J Ethnopharmacol, 2020, 260: 113066. Lee H, Heo J W, Kim A R, et al. Z-ajoene from crushed garlic alleviates cancer-induced skeletal muscle atrophy [J]. Nutrients, 2019, 11(11): 2724. 杨晨晓. 共载白藜芦醇/姜黄素的膜融合脂质体用于肿瘤恶液质肌肉萎缩的靶向递药和实验治疗研究[D]. 南昌: 南昌大学, 2024. Qiu Z L, Wo D, Zhong X M, et al. Babao Dan alleviates cancer cachexia in mice via inhibiting IL-6/STAT3 signaling pathway [J]. Integr Cancer Ther, 2023, 22: 15347354231168369. 王珍, 范铎, 裴正颖, 等. 基于网络药理学和动物实验探究二藤散结胶囊改善结肠癌恶病质肌肉萎缩的机制[J/OL]. 中医学报, (2025-09-01) [2026-08-17]. https:// link.cnki.net/urlid/41.1411.r.20250901.1304.026. Singh A, Yadav A, Phogat J, et al. Dynamics and interplay between autophagy and ubiquitin-proteasome system coordination in skeletal muscle atrophy [J]. Curr Mol Pharmacol, 2022, 15(3): 475-486. Martin A, Gallot Y S, Freyssenet D. Molecular mechanisms of cancer cachexia-related loss of skeletal muscle mass: Data analysis from preclinical and clinical studies [J]. J Cachexia Sarcopenia Muscle, 2023, 14(3): 1150-1167. 祝紫夏. 芍药苷缓解肿瘤恶病质肌萎缩及其作用机制研究[D]. 上海: 华东师范大学, 2024. Choi J W, Choi S Y, Lee H H L, et al. Glycyrrhiza uralensis attenuates TNF-α-induced muscle atrophy in myoblast cells through the Nrf2 and MAFbx signaling cascades [J]. Appl Biol Chem, 2022, 65: 16. 林毅, 王振飞, 肖静. 华蟾素片对CT26结肠腺癌诱导恶病质小鼠肌肉萎缩的影响[J]. 中外医疗, 2021, 40(4): 30-32. 李斌, 干润, 杨全军, 等. 中医不同治法方药对CT26结肠腺癌诱导小鼠恶病质肌肉萎缩的影响[J]. 中华中医药杂志, 2015, 30(5): 1696-1700. 王理槐, 窦娴, 陈晟, 等. 扶正口服液通过内质网应激途径改善癌症恶病质肌肉萎缩的机制研究[J]. 湖南中医药大学学报, 2022, 42(11): 1809-1815. Ge Z J, Liu D, Shang Y, et al. Magnolol inhibits myotube atrophy induced by cancer cachexia through myostatin signaling pathway in vitro [J]. J Nat Med, 2020, 74(4): 741-749. 王洮. 芪归相须干预肿瘤恶病质的机制研究[D]. 成都: 成都中医药大学, 2019. Zhang W L, Li N, Shen Q, et al. Establishment of a mouse model of cancer cachexia with spleen deficiency syndrome and the effects of atractylenolide I [J]. Acta Pharmacol Sin, 2020, 41(2): 237-248. 陈力. 苦参碱通过BDK调控肿瘤恶病质骨骼肌萎缩作用和机制研究[D]. 上海: 上海交通大学, 2019. Chen X Z, Wu Y P, Yang T H, et al. Salidroside alleviates Cachexia symptoms in mouse models of cancer cachexia via activating mTOR signalling [J]. J Cachexia Sarcopenia Muscle, 2016, 7(2): 225-232. Oelkrug R, Polymeropoulos E T, Jastroch M. Brown adipose tissue: Physiological function and evolutionary significance [J]. J Comp Physiol B, 2015, 185(6): 587-606. Shen Q, Miao C X, Zhang W L, et al. SiBaoChongCao exhibited anti-fatigue activities and ameliorated cancer cachexia in mice [J]. RSC Adv, 2019, 9(30): 17440-17456. Lu S S, Li Y W, Shen Q, et al. Carnosol and its analogues attenuate muscle atrophy and fat lipolysis induced by cancer cachexia [J]. J Cachexia Sarcopenia Muscle, 2021, 12(3): 779-795. 庞涛, 王绍展, 许维恒, 等. 木犀草素对模型小鼠癌性恶病质的改善作用[J]. 中国药房, 2015, 26(7): 882-885. 房智彦, 朱海燕, 淮文英, 等. 黄芪建中汤调控巨噬细胞M1/M2极化改善癌症恶病质小鼠脂肪消耗[J]. 中国实验方剂学杂志, 2026, 32(2): 61-69. 李斌, 万丽丽, 李颜, 等. 四君子汤对结肠腺癌荷瘤小鼠癌性恶病质的影响[J]. 中医杂志, 2014, 55(18): 1584-1587. 肖建东, 何守敏, 刘建郭, 等. 香砂六君丸对癌症恶病质的疗效及机制研究[J]. 光明中医, 2025, 40(20): 4465-4469. 周丽, 郭勇. 益气养阴中药改善小鼠模型癌性恶病质实验研究[J]. 实用中医药杂志, 2012, 28(4): 264-266. 李勇, 梁亚州, 丁永丽, 等. PTD4-Cu/ZnSOD融合蛋白对缺氧复氧损伤模型大鼠心肌细胞H9C2心肌线粒体功能的影响[J]. 中西医结合心脑血管病杂志, 2018, 16(11): 1497-1501. 郭苇, 肖敏, 左谦, 等. 参芪扶正注射液对结肠癌小鼠恶液质后骨骼肌线粒体功能的影响[J]. 中草药, 2019, 50(24): 6059-6063. 罗星, 潘博, 傅剑锋, 等. 健脾消癌方调控iNOS-ARG1轴诱导线粒体功能障碍抑制结肠癌进展[J]. 中国实验方剂学杂志, 2026, 32(13): 99-111. Ourique F, Kviecinski M R, Bagolin do Nascimento A. Editorial: Nutritional modulation of immune function in cancer [J]. Front Nutr, 2023, 10: 1290026. Wang H, Chan Y L, Li T L, et al. Improving cachectic symptoms and immune strength of tumour-bearing mice in chemotherapy by a combination of Scutellaria baicalensis and Qing-Shu-Yi-Qi-Tang [J]. Eur J Cancer, 2012, 48(7): 1074-1084. 叶循雯, 叶兴涛, 刘帆. 康艾注射液联合醋酸甲地孕酮片改善晚期肿瘤恶液质临床观察[J]. 新中医, 2017, 49(1): 63-65. 张益明. 十全大补汤辅助肠内营养支持对结直肠癌根治术患者营养状况及免疫功能的影响[J]. 新中医, 2022, 54(12): 170-174. 王彬彬, 陈培丰, 舒琦瑾. 参麦注射液对小鼠结肠腺癌26恶病质相关基因表达谱影响的实验研究[J]. 浙江中医药大学学报, 2009, 33(4): 472-474. 冯宇, 呼健. 人参养荣汤对肿瘤恶液质模型小鼠肠道损伤的影响[J]. 中国中医药现代远程教育, 2025, 23(12): 86-89.
PDF下载
全屏
31
5
关闭全屏
北京市海淀区学院南路86号
010-62662699（运营及技术支持）
qkjq@cast.org.cn
